XML 39 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2020
Mar. 19, 2021
Jun. 30, 2020
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2020    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Entity Registrant Name Inozyme Pharma, Inc.    
Entity Central Index Key 0001693011    
Entity Incorporation, State or Country Code DE    
Entity File Number 001-39397    
Entity Tax Identification Number 38-4024528    
Entity Address, Address Line One 321 Summer Street    
Entity Address, Address Line Two Suite 400    
Entity Address, City or Town Boston    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02210    
City Area Code 857    
Local Phone Number 330-4340    
Title of 12(b) Security Common stock, par value $0.0001 per share    
Trading Symbol INZY    
Security Exchange Name NASDAQ    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   23,464,130  
Entity Public Float     $ 0
Documents Incorporated by Reference

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2020. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.